Healthcare
Dianthus Therapeutics to Participate in Three Investor Conferences During September
NEW YORK and WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in three investor conferences. Wells Fargo 21st Annual Healthcare Conference: Marino Garcia, CEO, and Ryan Savitz, EVP, CFO & CBO of Dianthus Therapeutics, will host one-on-one investor meetings on Sep
About this update from Dianthus Therapeutics, Inc.
NEW YORK and WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in three investor conferences. Webcasts of the presentations at the Citi and Cantor conferences may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website . About Dianthus Therapeutics Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases. To learn more, please visit www.dianthustx.com and follow us on LinkedIn . Contact Jennifer Davis Ruff Dianthus Therapeutics [email protected]
View stock analysis, news, and events for Dianthus Therapeutics, Inc.